The recent trade deal between President Donald Trump and the European Union has brought about significant changes in the pharmaceutical industry. With the introduction of a 15% tariff on pharmaceutical imports, analysts are predicting billions in additional costs for the industry. Diederik Stadig from ING estimates these tariffs could result in $13 billion more in expenses, potentially passed on to consumers. On the other hand, Bernstein’s Courtney Breen forecasts an even higher impact, suggesting that pharma expenses could increase by $19 billion due to the new duties. However, analysts at Jefferies offer a more optimistic view, stating that the impact of the 15% levy is ‘less bad’ than expected and will be manageable for the industry. They highlight that many companies, especially larger players, already have substantial operations in the U.S. and could potentially avoid the costs of import tariffs. Despite the news of these tariffs, the S&P Biotech ETF remained largely unaffected, indicating a sense of stability in the biotechnology sector. The trade deal also brings relief to European pharma exporters, as they will no longer face targeted tariffs under the ongoing Section 232 national security investigation initiated by Trump’s Department of Commerce. This investigation, which began in April, is expected to conclude by August 1, although the process is still ongoing. The looming threat of tariffs has been a concern for the industry since Trump’s initial mention of them in February. While the president recently suggested that tariffs could potentially rise to 200%, he has given companies a grace period of about a year to adjust their supply chains. In response to these uncertainties, many major industry players have committed to significant investments in U.S. manufacturing. Companies like AstraZeneca, Johnson & Johnson, Roche, Regeneron, Eli Lilly, and Sanofi have all announced multi-billion-dollar investments in their U.S. operations, signaling a shift towards more localized production. The implications of these tariffs and the subsequent trade deal are complex and multifaceted, with varying opinions on the overall impact on the pharmaceutical industry.
Read more from biospace.com